PMID- 10022543
OWN - NLM
STAT- MEDLINE
DCOM- 19990413
LR  - 20061115
IS  - 1043-0342 (Print)
IS  - 1043-0342 (Linking)
VI  - 10
IP  - 2
DP  - 1999 Jan 20
TI  - High level of retrovirus-mediated gene transfer into dendritic cells derived from 
      cord blood and mobilized peripheral blood CD34+ cells.
PG  - 175-87
AB  - Dendritic cells (DCs), the most potent antigen-presenting cells, can be generated 
      from CD34+ hematopoietic stem cells and used for generating therapeutic immune 
      responses. To develop immunotherapy protocols based on genetically modified DCs, 
      we have investigated the conditions for high-level transduction of a large amount 
      of CD34+-derived DCs. Thus, we have used an efficient and clinically applicable 
      protocol for the retroviral transduction of cord blood (CB) or mobilized 
      peripheral blood (MPB) CD34+ cells based on infection with gibbon ape leukemia 
      virus (GALV)-pseudotyped retroviral vectors carrying the nls-LacZ reporter gene. 
      Infected cells have been subsequently cultured under conditions allowing their 
      dendritic differentiation. The results show that using a growth factor 
      combination including granulocyte-macrophage colony-stimulating factor plus tumor 
      necrosis factor alpha plus interleukin 4 plus stem cell factor plus Flt3 ligand, 
      more than 70% of DCs derived from CB or MPB CD34+ cells can be transduced. 
      Semiquantitative PCR indicates that at least two proviral copies per cell were 
      detected. Transduced DCs retain normal immunophenotype and potent T cell 
      stimulatory capacity. Finally, by using a semisolid methylcellulose assay for 
      dendritic progenitors (CFU-DCs), we show that more than 90% of CFU-DCs can be 
      transduced. Such a highly efficient retrovirus-mediated gene transfer into 
      CD34+-derived DCs makes it possible to envision the use of this methodology in 
      clinical trials.
FAU - Movassagh, M
AU  - Movassagh M
AD  - Biologie et Therapie des Pathologies Immunitaires, ESA CNRS 7087 CERVI, CHU Pitie 
      Salpetriere, Paris, France.
FAU - Baillou, C
AU  - Baillou C
FAU - Cosset, F L
AU  - Cosset FL
FAU - Klatzmann, D
AU  - Klatzmann D
FAU - Guigon, M
AU  - Guigon M
FAU - Lemoine, F M
AU  - Lemoine FM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hum Gene Ther
JT  - Human gene therapy
JID - 9008950
RN  - 0 (Antigens, CD34)
RN  - 0 (DNA Primers)
SB  - IM
MH  - Antigens, CD34/*immunology
MH  - Base Sequence
MH  - Cell Division
MH  - Cell Line
MH  - DNA Primers
MH  - Dendritic Cells/immunology/*metabolism
MH  - Fetal Blood/*cytology
MH  - *Gene Transfer Techniques
MH  - Hematopoietic Stem Cell Mobilization
MH  - Humans
MH  - Immunophenotyping
MH  - Retroviridae/*genetics
MH  - T-Lymphocytes/cytology
MH  - Transduction, Genetic
EDAT- 1999/02/18 00:00
MHDA- 1999/02/18 00:01
CRDT- 1999/02/18 00:00
PHST- 1999/02/18 00:00 [pubmed]
PHST- 1999/02/18 00:01 [medline]
PHST- 1999/02/18 00:00 [entrez]
AID - 10.1089/10430349950018977 [doi]
PST - ppublish
SO  - Hum Gene Ther. 1999 Jan 20;10(2):175-87. doi: 10.1089/10430349950018977.